Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.54 |
| ▸ | HTR3A | P46098 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | THPO | P40225 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | APEX1 | P27695 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25101015 | 1.00 | TAAR1 (0.54) | TAAR1HIF1AHTR3ATSHRNFKB1 | |
| SCHEMBL6320570 | 0.83 | TAAR1 (0.50) | TAAR1HIF1AHTR3ATSHRNFKB1 | |
| SCHEMBL16327150 | 0.83 | AOC3 (0.48) | TAAR1ALDH1A1SMN1; SMN2SLC6A2SLC6A4 | |
| SCHEMBL1205131 | 0.81 | AOC3 (0.72) | TAAR1KDM4ESLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6281264 | 0.81 | AOC3 (0.72) | ALDH1A1SMN1; SMN2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1239178 | 0.81 | AOC3 (0.47) | TAAR1HIF1ANFKB1HTR1ATHPO | |
| SCHEMBL529255 | 0.81 | AOC3 (0.52) | TAAR1HIF1AHTR3ATSHRNFKB1 | |
| SCHEMBL12238827 | 0.80 | TAAR1 (0.47) | TAAR1HIF1AHTR3ATSHRNFKB1 | |
| SCHEMBL29633156 | 0.80 | TAAR1 (0.47) | TAAR1HIF1AHTR3ATSHRNFKB1 | |
| SCHEMBL804251 | 0.80 | AOC3 (0.70) | TAAR1TDP1KDM4ESMN1; SMN2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6924283-B2 | 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carbothioamides as antiviral agents | PFIZER (US) | 2005-08-02 | — | — | US | claimed |
| US-6861438-B2 | Antiviral agents | PFIZER (US) | 2005-03-01 | — | — | US | claimed |
| US-6852731-B2 | Antiviral compounds | PFIZER (US) | 2005-02-08 | — | — | US | claimed |
| US-20040242884-A1 | ANTIVIRAL COMPOUNDS | PHARMACIA & UPJOHN COMPANY | 2004-12-02 | — | — | US | claimed |
| US-20040138449-A1 | Antiviral agents | PHARMACIA & UPJOHN COMPANY | 2004-07-15 | — | — | US | claimed |
| EP-1421088-A1 | 4-THIOXO-4,7-DIHYDRO-THIENO 2,3-B]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2004-05-26 | — | — | EP | claimed |
| EP-1421089-A1 | 4-THIOXO-4,7-DIHYDRO-THIENO 2,3-b]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS | Pharmacia & Upjohn Company (US) | 2004-05-26 | — | — | EP | claimed |
| US-6620810-B2 | Treating a herpesvirus infection, atherosclerosis or restenosis | PHARMACIA & UPJOHN COMPANY | 2003-09-16 | — | — | US | claimed |
| US-20030109542-A1 | 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2003-06-12 | — | — | US | claimed |
| US-20030100536-A1 | 4-Thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carbothioamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2003-05-29 | — | — | US | claimed |
| WO-2003020730-A1 | 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-B]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-03-13 | — | — | WO | claimed |
| WO-2003020729-A1 | 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOXAMIDES AS ANT IVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-03-13 | — | — | WO | claimed |
| WO-2003020728-A1 | 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-03-13 | — | — | WO | claimed |
| JP-2002539130-A | — | — | 2002-11-19 | — | — | JP | claimed |
| EP-1159279-B1 | 4-OXO-4,7-DIHYDRO-THIENO[2,3-B]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS | UPJOHN CO (US) | 2002-10-16 | — | — | EP | claimed |
| US-20020006937-A1 | 4-OXO-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-01-17 | — | — | US | claimed |
| EP-1159279-A2 | 4-OXO-4,7-DIHYDRO-THIENO[2,3-B]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-12-05 | — | — | EP | claimed |
| US-6239142-B1 | HERPES VIRUS INFECTION | PHARMACIA & UPJOHN COMPANY | 2001-05-29 | — | — | US | claimed |
| WO-2000053610-A2 | 4-OXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2000-09-14 | — | — | WO | claimed |
| US-20210087593-A1 | N-ALKYLATION OF ALKALOID COMPOUNDS | WILLOW BIOSCIENCES INC (CA) | 2021-03-25 | — | — | US | disclosed |
| US-20210087593-A1 | N-ALKYLATION OF ALKALOID COMPOUNDS | WILLOW BIOSCIENCES INC (CA) | 2021-03-25 | — | — | US | disclosed |
| US-10676767-B2 | Methods and compositions for making ephedrine and related alkaloid compounds | Willow Biosciences Inc. (CA) | 2020-06-09 | — | — | US | disclosed |
| US-20180179561-A1 | Methods and Compositions For Making Ephedrine and Related Alkaloid Compounds | Willow Biosciences Inc. (CA) | 2018-06-28 | — | — | US | disclosed |
| EP-3314001-A1 | METHODS AND COMPOSITIONS FOR MAKING EPHEDRINE AND RELATED ALKALOID COMPOUNDS | Serturner Corp. (CA) | 2018-05-02 | — | — | EP | disclosed |
| WO-2016205939-A1 | METHODS AND COMPOSITIONS FOR MAKING EPHEDRINE AND RELATED ALKALOID COMPOUNDS | SERTURNER CORP. (CA) | 2016-12-29 | — | — | WO | disclosed |
| US-7858796-B2 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2010-12-28 | — | — | US | disclosed |
| US-7858796-B2 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2010-12-28 | — | — | US | disclosed |
| US-20070254873-A1 | Chemical Compounds | GLAXO GROUP LIMITED (GB) | 2007-11-01 | — | — | US | disclosed |
| US-20070254873-A1 | Chemical Compounds | GLAXO GROUP LIMITED (GB) | 2007-11-01 | — | — | US | disclosed |
| US-6924283-B2 | 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carbothioamides as antiviral agents | PFIZER (US) | 2005-08-02 | — | — | US | disclosed |
| US-6861438-B2 | Antiviral agents | PFIZER (US) | 2005-03-01 | — | — | US | disclosed |
| US-6852731-B2 | Antiviral compounds | PFIZER (US) | 2005-02-08 | — | — | US | disclosed |
| US-20040242884-A1 | ANTIVIRAL COMPOUNDS | PHARMACIA & UPJOHN COMPANY | 2004-12-02 | — | — | US | disclosed |
| US-20040138449-A1 | Antiviral agents | PHARMACIA & UPJOHN COMPANY | 2004-07-15 | — | — | US | disclosed |
| US-20040102473-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W (US) | 2004-05-27 | — | — | US | disclosed |
| EP-1421089-A1 | 4-THIOXO-4,7-DIHYDRO-THIENO 2,3-b]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS | Pharmacia & Upjohn Company (US) | 2004-05-26 | — | — | EP | disclosed |
| EP-1421088-A1 | 4-THIOXO-4,7-DIHYDRO-THIENO 2,3-B]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2004-05-26 | — | — | EP | disclosed |
| US-6620810-B2 | Treating a herpesvirus infection, atherosclerosis or restenosis | PHARMACIA & UPJOHN COMPANY | 2003-09-16 | — | — | US | disclosed |
| US-20030109542-A1 | 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2003-06-12 | — | — | US | disclosed |
| US-20030100536-A1 | 4-Thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carbothioamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2003-05-29 | — | — | US | disclosed |
| WO-2003020730-A1 | 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-B]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-03-13 | — | — | WO | disclosed |
| WO-2003020728-A1 | 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-03-13 | — | — | WO | disclosed |
| WO-2003020729-A1 | 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOXAMIDES AS ANT IVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-03-13 | — | — | WO | disclosed |
| US-6495683-B2 | HERPES VIRUS | PHARMACIA AND UPJOHN COMPANY | 2002-12-17 | — | — | US | disclosed |
| EP-1159279-B1 | 4-OXO-4,7-DIHYDRO-THIENO[2,3-B]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS | UPJOHN CO (US) | 2002-10-16 | — | — | EP | disclosed |
| US-20020006937-A1 | 4-OXO-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-01-17 | — | — | US | disclosed |
| EP-1159279-A2 | 4-OXO-4,7-DIHYDRO-THIENO[2,3-B]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-12-05 | — | — | EP | disclosed |
| US-6239142-B1 | HERPES VIRUS INFECTION | PHARMACIA & UPJOHN COMPANY | 2001-05-29 | — | — | US | disclosed |
| WO-2000053610-A2 | 4-OXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2000-09-14 | — | — | WO | disclosed |
| US-5994507-A | CONTACTING AQUEOUS LIQUID CONTAINING ALBUMIN WITH A COMPOUND CONTAINING THE SCAFFOLD--C(=O)-NH-C(=C-)-C(=O)- AND HAVING BEEN PRE-CHECKED TO BIND TO THE ALBUMIN; FOR REMOVAL OF ALBUMIN FROM A SOLUTION OR FOR PURIFICATION OF ALBUMIN | AMERSHAM PHARMACIA BIOTECH AB (SE) | 1999-11-30 | — | — | US | disclosed |
| US-5994507-A | CONTACTING AQUEOUS LIQUID CONTAINING ALBUMIN WITH A COMPOUND CONTAINING THE SCAFFOLD--C(=O)-NH-C(=C-)-C(=O)- AND HAVING BEEN PRE-CHECKED TO BIND TO THE ALBUMIN; FOR REMOVAL OF ALBUMIN FROM A SOLUTION OR FOR PURIFICATION OF ALBUMIN | AMERSHAM PHARMACIA BIOTECH AB (SE) | 1999-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100536-A1 | 4-Thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carbothioamides as antiviral agents | TPMT, TK1, TYMP | TAAR1 692/4885HIF1A 1546/4885HTR3A 4248/4885 |
| US-20040102473-A1 | Method of preventing or treating atherosclerosis or restenosis | LDLR, MSR1, TGFB1 | TAAR1 703/4885HIF1A 179/4885HTR3A 3669/4885 |
| US-20040242884-A1 | ANTIVIRAL COMPOUNDS | ZC3HAV1, IRF3, IFNAR1 | TAAR1 3943/4885HIF1A 1264/4885HTR3A 3657/4885 |
| US-20040138449-A1 | Antiviral agents | IRF3, IFNAR1, EIF2AK2 | TAAR1 3903/4885HIF1A 1529/4885HTR3A 3667/4885 |
| US-20020006937-A1 | 4-OXO-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as antiviral agents | IRF3, IL4, ZC3HAV1 | TAAR1 3738/4885HIF1A 1101/4885HTR3A 3839/4885 |
| US-10676767-B2 | Methods and compositions for making ephedrine and related alkaloid compounds | PNMT, GNMT, BHMT | TAAR1 559/4885HIF1A 2498/4885HTR3A 152/4885 |
| US-20070254873-A1 | Chemical Compounds | IKBKG, NFKBIA, RELA | TAAR1 2652/4885HIF1A 1871/4885HTR3A 2740/4885 |
| US-20030109542-A1 | 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as antiviral agents | IRF3, IRAK4, IFNAR1 | TAAR1 1124/4885HIF1A 826/4885HTR3A 4151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.